Azatadine


Full Generic Medicine Info
Dosage/Direction for Use

Oral
Allergic conditions
Adult: 1 mg bid increased to 2 mg bid if needed.
Child: 6-12 yr: 0.5-1 mg bid.
Administration
May be taken with or without food. May be taken w/ food or milk if stomach upset occurs.
Contraindications
Neonates; patients receiving MAOI therapy; lactation.
Special Precautions
Angle-closure glaucoma, increased intraocular pressure, stenosing peptic ulcer, pyloroduodenal obstruction, epilepsy; renal and hepatic impairment. May impair ability to drive or operate machinery; pregnancy.
Adverse Reactions
Drowsiness, dizziness, headache, fatigue, nervousness; anticholinergic effects, thick bronchial secretions; arthralgia; pharyngitis; increased appetite, wt gain, nausea, diarrhoea, abdominal pain, dry mouth; impaired alertness.
Drug Interactions
Potentiates CNS depression with other CNS depressants e.g. TCAs, procarbazine and alcohol.
Potentially Fatal: MAOIs enhance anticholinergic side effect of azatadine. Enhance depressant action of anxiolytic and sedating drugs.
Food Interaction
Alcohol may enhance sedative effects.
Action
Azatadine has anticholinergic and antiserotonin activity. It inhibits mediator release from mast cells by preventing calcium entry through voltage-dependent calcium channels.
Absorption: Absorbed from the GI tract (oral); peak plasma concentrations after 4 hr.
Metabolism: Minimal metabolism.
Excretion: Via the urine (as unchanged drug and metabolites); 9-12 hr (elimination half-life).
Storage
Oral: Store at 2-30°C.
ATC Classification
R06AX09 - azatadine ; Belongs to the class of other antihistamines for systemic use.
Disclaimer: This information is independently developed by CIMS based on azatadine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in